Axogen, Inc. Q3 2025 Financial Results and Business Highlights

Axogen, Inc. reported its third quarter 2025 financial results, showing a 23.5% increase in revenue to $60.1 million compared to the same period in 2024. The company also raised its full-year revenue guidance to at least 19% growth, or $222.8 million. Gross margin for the quarter improved to 76.6%, up from 74.9% in Q3 2024. Net income for the quarter was $0.7 million, or $0.01 per share, compared to a net loss of $1.9 million, or $0.04 per share, in the prior year. Adjusted net income was $6.1 million, or $0.12 per share, and adjusted EBITDA was $9.2 million. The company highlighted several business achievements, including the recognition of nerve allograft as a standard medical practice by the American Association of Hand Surgery (AAHS) and the American Society for Reconstructive Microsurgery (ASRM). Axogen also expects FDA approval for its Avance® Nerve Graft Biologics License Application (BLA) by December 5, 2025.